Research reveals mechanism that influences cancer cells to die

October 02, 2002

NEW YORK, October 2, 2002 - Research published in today's online version of Nature sheds light on why certain cancer cells die (apoptosis) in response to chemotherapy, while others stop proliferating (citostasis) and try to repair the damaging effects of the drug. For years, scientists have tried to understand what determines this choice - citostasis versus apoptosis - in order to influence that decision in favor of cell death during the course of treatment.

Researchers at Memorial Sloan-Kettering Cancer Center demonstrated that cancer cells containing a high level of a protein called Myc cannot activate the production of the p21 gene, which inhibits cell division. According to the study's authors, Myc binds to p21 and blocks its ability to stop cell proliferation, creating conditions that allow the cancer cells to die off.

"Our work reveals a way we might coax cells to favor apoptosis instead of citostasis in order to increase the effectiveness of chemotherapy," said Howard Hughes Medical Institute Investigator Joan Massagué, PhD, Chairman of the Cell Biology Program at Memorial Sloan-Kettering and senior author of the study. "Now, time and more research need to reveal how feasible this strategy would be in the clinic."

Memorial Sloan Kettering Cancer Center

Related Chemotherapy Articles from Brightsurf:

Chemotherapy is used to treat less than 25% of people with localized sarcoma
UCLA researchers have found that chemotherapy is not commonly used when treating adults with localized sarcoma, a rare type of cancer of the soft tissues or bone.

Starved cancer cells became more sensitive to chemotherapy
By preventing sugar uptake, researchers succeeded in increasing the cancer cells' sensitivity to chemotherapeutic treatment.

Vitamin D could help mitigate chemotherapy side effects
New findings by University of South Australia researchers reveal that Vitamin D could potentially mitigate chemotherapy-induced gastrointestinal mucositis and provide relief to cancer patients.

Less chemotherapy may have more benefit in rectal cancer
GI Cancers Symposium: Colorado study of 48 patients with locally advanced rectal cancer receiving neoadjuvant chemotherapy, found that patients receiving lower-than-recommended doses in fact saw their tumors shrink more than patients receiving the full dose.

Male fertility after chemotherapy: New questions raised
Professor Delb├Ęs, who specializes in reproductive toxicology, conducted a pilot study in collaboration with oncologists and fertility specialists from the McGill University Health Centre (MUHC) on a cohort of 13 patients, all survivors of pediatric leukemia and lymphoma.

'Combo' nanoplatforms for chemotherapy
In a paper to be published in the forthcoming issue in NANO, researchers from Harbin Institute of Technology, China have systematically discussed the recent progresses, current challenges and future perspectives of smart graphene-based nanoplatforms for synergistic tumor therapy and bio-imaging.

Nanotechnology improves chemotherapy delivery
Michigan State University scientists have invented a new way to monitor chemotherapy concentrations, which is more effective in keeping patients' treatments within the crucial therapeutic window.

Novel anti-cancer nanomedicine for efficient chemotherapy
Researchers have developed a new anti-cancer nanomedicine for targeted cancer chemotherapy.

Ending needless chemotherapy for breast cancer
A diagnostic test developed at The University of Queensland might soon determine if a breast cancer patient requires chemotherapy or would receive no benefit from this gruelling treatment.

A homing beacon for chemotherapy drugs
Killing tumor cells while sparing their normal counterparts is a central challenge of cancer chemotherapy.

Read More: Chemotherapy News and Chemotherapy Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to